New drug shows promise for Hard-to-Treat cancers in early trial

NCT ID NCT05382364

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the safety of tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancer that has worsened after standard treatments. Researchers will monitor side effects and how the drug moves through the body. The goal is to see if tucatinib is safe enough for further study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm colorectal cancer colorectal neoplasm gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS COLORECTAL CANCER GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (GEC) METASTATIC HER2+ ADVANCED BREAST CANCER

Contacts and locations

Show contact details

Locations

Fudan University Shanghai Cancer Center

Shanghai, 201321, China
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Hunan Cancer Hospital

Changsha, Hunan, 421000, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, 300060, China